Organon

Executive Summary:

Amid profound global demographic shifts, declining fertility rates, aging populations, and delayed childbearing have emerged as shared challenges worldwide. In response, a strong international consensus is forming around safeguarding reproductive rights, reducing the costs of childbirth, and enhancing reproductive care. China is currently navigating this critical demographic transition with remarkable foresight. We deeply recognize that fostering a fertility-friendly society is not merely a response to the public’s aspiration for a better life, but a visionary cornerstone for driving China’s high-quality population development and modernization.

As a multinational healthcare company deeply rooted in women’s health, Organon’s vision aligns seamlessly with China’s 15th Five-Year Plan and national health priorities. Guided by our grassroots research and deep respect for local needs, we respectfully share our reflections across five core areas, hoping to contribute a constructive perspective:

●Adolescent Fertility Protection: We see encouraging progress in reproductive health education. Building on this, there is a shared opportunity to further enrich sex education and tailor services specifically for youth. 

● Fertility Assessment & Preconception Care: Commendable strides have been made in establishing assessment clinics. We look forward to seeing the continued standardization of these systems and broader access for the reproductive-age population. 

● Assisted Reproductive Technology (ART) Access: We celebrate the milestone achievements of expanding medical insurance coverage for ART across multiple provinces, and we fully support the ongoing optimization of top-level design and diverse payment mechanisms. 

● Fertility Preservation: As regulatory frameworks proactively adapt to demographic changes, the institutional management of fertility preservation for single women remains a valuable area for continued exploration. 

● Prevention of Birth Defects Caused by Genetic Rare Diseases: A robust three-tiered prevention system has been successfully established. Within this framework, we see great potential in further emphasizing primary prevention—specifically preconception screening for monogenic disorders— and enhancing clinical coordination.

Anchored in our unwavering commitment to clinical safety and efficacy, we respectfully offer the following five actionable suggestions for consideration, standing ready to assist in their implementation: 

1. Strengthen public awareness of fertility protection and improve reproductive health service systems of adolescents.  

2. Build a robust fertility assessment system to expand nationwide access to preconception care. 

3. Improve multi-channel payment policies for ART to Reduce Patient Burdens. 

4. Refine fertility preservation regulations, standardize the safe clinical application of related technologies. 

5. Reinforce the three-tiered birth defect prevention system, maximizing the impact of primary prevention for monogenic disorders. 

Organon is dedicated to advancing R&D and service innovation strictly guided by clinical needs and patient benefits. We firmly believe that under the wise guidance of government, and through the collective efforts of the industry and society, China will successfully forge a new fertility- friendly paradigm—one that is “accessible, affordable, and equitable.” 

As a deeply committed participant in women’s health, Organon is proud to be part of China’s dynamic healthcare ecosystem and evolving healthcare ecosystem, reaching millions of patients each year across therapeutic areas. Guided by our strategy, “In China, for China; In China, for Global,” we are deepening collaboration with local partners, combining our global expertise with local strong innovation capabilities to bring meaningful solutions to patients. Organon is committed to deepening our presence in China and contributing to shared priorities, including the goals of Healthy China.

Download the full report：Building a Fertility-Friendly Society: Insights and Recommendations from the Perspective of the Women’s Health Industry